Exicure Inc
exicuretx.comExicure Inc (NASDAQ: XCUR) is a biotechnology company that historically developed nucleic acid therapies targeting ribonucleic acid but suspended all research and development activities in September 2022. The company generates minimal revenue through licensing agreements tied to its legacy patent portfolio, having received a $500,000 upfront payment in February 2024 from a licensing agreement for patents related to one historical drug candidate, along with entitlement to modest royalties. As of the 10-K filed March 25, 2026, Exicure is also party to a License and Collaboration Agreement with GPCR USA, whose Phase 2 clinical trial in blood cancer patients completed in January 2026, with Exicure committed to a $1,000,000 milestone payment to GPCR USA in shares of common stock in the second quarter of 2026. The company is headquartered in Chicago, Illinois, with Jung Soo Kim serving as Chief Executive Officer. Exicure reported net losses for both fiscal years 2024 and 2025 and carries no disclosed product revenue.
Products & Services
Legacy nucleic acid therapy patent portfolio licensed to third parties. Collaboration with GPCR USA involving GPC-100 (a small molecule antagonist targeting a chemokine receptor) combined with propranolol for stem cell mobilization in Multiple Myeloma patients, with a Phase 2 clinical trial completed January 2026.
Revenue Model
Licensing fees and royalties from legacy nucleic acid therapy patents. The company received a $500,000 upfront licensing payment in February 2024 and is entitled to modest royalties on one historical drug candidate. No product or collaboration revenue is disclosed for FY2025.
Customers & Markets
Licensees of nucleic acid therapy patents. End market exposure is to blood cancer and hematopoietic stem cell transplantation via the GPCR USA collaboration. No customer concentration data disclosed in the filing excerpts.
Geographic Exposure
Headquartered in Chicago, Illinois. Formed a South Korean subsidiary, KC Creation Co., Ltd., in March 2025, which was subsequently sold in November 2025. No other geographic revenue breakdown disclosed.
Financial Snapshot
Loading...
